Interfering Substances in Total Protein Assays

By Dr. Zubair Khalid, DVM, MS, PhD · 2026-08-21

Quick Answer

• Match the assay chemistry to your sample buffer: BCA and Lowry tolerate most detergents but fail with reducing agents, while Bradford tolerates reducing agents but fails with detergents.
• Remove or dilute interfering substances before quantification using dialysis, desalting columns, or acid precipitation, then verify recovery with a spike-and-recovery control.
• No single protein assay works for every sample, so validate your chosen method against your specific buffer and protein combination before trusting reported concentrations.

At a Glance

Understanding Protein Assay Chemistry and Interference Mechanisms

Protein quantification rests on a small set of chemical reactions that convert protein concentration into a measurable signal. Each reaction depends on specific reagents, pH conditions, and incubation parameters. When a sample contains substances other than protein, those substances can alter the reaction in ways that produce falsely high or falsely low readings. Understanding the chemistry behind each assay helps you predict which interferences matter for your samples and which mitigation strategy will work.

The BCA assay relies on the biuret reaction, where peptide bonds reduce cupric ions to cuprous ions under alkaline conditions. The reduced copper then chelates with bicinchoninic acid to form a purple-colored complex that absorbs light at 562 nm. Because the reaction depends on copper reduction, any reducing agent in your sample will also reduce cupric ions and inflate the signal. Common reducing agents used in protein purification include dithiothreitol (DTT), beta-mercaptoethanol, and tris(2-carboxyethyl)phosphine (TCEP). Even trace amounts of these compounds can produce substantial background signal in the BCA assay.

The Bradford assay uses Coomassie Brilliant Blue G-250 dye, which binds to arginine and aromatic amino acid residues. The dye shifts from a red-brown form to a blue form upon protein binding, with absorbance measured at 595 nm. Because the dye binds to specific amino acids instead of peptide bonds, the assay responds differently to different proteins. More importantly for interference, the dye interacts with detergents. Ionic detergents such as sodium dodecyl sulfate (SDS) and cetyltrimethylammonium bromide (CTAB) can bind the dye and cause precipitation or spectral shifts. Nonionic detergents like Triton X-100 and Tween-20 interfere at higher concentrations by stabilizing the dye in a form that absorbs at the measurement wavelength.

The Lowry assay combines the biuret reaction with the Folin-Ciocalteu reagent, which reacts primarily with tyrosine and tryptophan residues. The reaction produces a blue color measured at 750 nm. Like the BCA assay, the Lowry method is sensitive to reducing agents because the Folin reagent can be consumed by sample components. EDTA and other chelators interfere by sequestering the copper ions needed for the reaction.

The biuret assay is the simplest of the colorimetric methods, measuring the copper-peptide bond complex directly at 540 nm. It has lower sensitivity than BCA or Bradford but is less susceptible to many common interferences. However, reducing agents still interfere because they reduce the cupric ions, and ammonium salts can compete with the copper complex.

The Pierce 660 nm assay uses a proprietary dye that binds protein and shifts absorbance to 660 nm. This assay was designed to be compatible with reducing agents and detergents at concentrations commonly used in protein research. However, very high concentrations of reducing agents can still cause problems, and the assay shows protein-to-protein variability similar to other dye-binding methods.

Direct UV absorbance at 280 nm (A280) measures aromatic amino acids, primarily tryptophan and tyrosine. This method requires no reagents, consumes no sample, and is compatible with virtually any buffer component that does not absorb at 280 nm. The main interferences are nucleic acids, which absorb strongly at 260 nm and have some absorbance at 280 nm, and buffer components such as imidazole, which absorbs near this wavelength. Turbidity from particulates or lipids also scatters light and inflates absorbance readings.

Fluorometric assays, such as those using fluorescamine or the CBQCA reagent, offer high sensitivity but introduce new interference classes. Detergents can quench fluorescence or alter the reaction kinetics. Some fluorometric reagents react with primary amines, so any buffer containing free amines, such as Tris or glycine, will compete with protein amino groups and reduce signal.

The choice of assay should follow from the composition of your sample buffer and the concentration range of your protein. If you are working with purified protein in a simple phosphate buffer, A280 or Bradford may serve well. If you are quantifying protein in cell lysates containing detergents and reducing agents, BCA with a compatible buffer or Pierce 660 nm may be more appropriate. The key is to know what is in your sample before you choose the assay.

Selecting the Appropriate Assay for Your Sample Buffer

The first decision in protein quantification is matching the assay to your buffer composition. This decision determines whether you can measure your sample directly or whether you need to remove interfering substances first. The table below summarizes the compatibility of common buffer components with each assay type.

When your buffer contains a component that interferes with your preferred assay, you have three options. First, you can switch to a different assay that tolerates that component. Second, you can dilute the sample so that the interfering substance falls below its threshold concentration. Third, you can remove the interfering substance before measurement.

Dilution is the simplest approach but has limits. If your protein concentration is low, dilution may push you below the detection limit of the assay. If the interfering substance is present at very high concentration, you may need to dilute so much that protein becomes undetectable. A practical approach is to test a dilution series of your sample and check whether the calculated protein concentration remains consistent across dilutions. If the concentration appears to change with dilution, interference is likely present.

Removal of interfering substances requires additional steps that can introduce their own problems. Dialysis removes small molecules but takes hours and can dilute your sample. Desalting columns are faster but also dilute the sample and may bind some proteins. Acid precipitation with trichloroacetic acid or acetone precipitates protein while leaving many small molecules in solution, but some proteins do not precipitate efficiently and resolubilization can be incomplete.

The choice of assay also depends on the protein concentration range you expect. BCA and Lowry assays have working ranges of approximately 20 to 2000 micrograms per milliliter. Bradford is more sensitive, working from about 1 to 1500 micrograms per milliliter depending on the formulation. A280 works best above 100 micrograms per milliliter for a typical protein. Fluorometric assays can detect nanogram quantities but require more careful calibration.

Protein-to-protein variability is another consideration. Bradford and Lowry assays respond differently to different proteins because they depend on specific amino acid residues. If your standard protein, typically bovine serum albumin, has a different amino acid composition than your sample protein, the calculated concentration will be inaccurate. BCA and A280 show less protein-to-protein variability, though A280 depends heavily on tryptophan and tyrosine content.

For samples containing nucleic acids, A280 requires a correction based on the A260/A280 ratio. A ratio of approximately 1.8 indicates pure protein, while higher ratios indicate nucleic acid contamination. The standard correction subtracts a fraction of the A260 reading from the A280 reading, but this correction assumes a specific nucleic acid composition and can introduce error. If nucleic acids are present in significant amounts, a colorimetric assay that does not respond to nucleic acids may be more reliable.

Practical Workflow for Validating Assay Compatibility

Before you trust any protein concentration measurement, you should validate that your assay works correctly with your specific sample buffer and protein. This validation takes about an hour and can save days of troubleshooting later. The workflow below outlines the steps for a spike-and-recovery experiment, which is the standard method for detecting interference.

Prepare a protein standard at a known concentration in your sample buffer. If you are using bovine serum albumin, prepare a stock solution at 2 milligrams per milliliter in the same buffer that contains your protein of interest. Also prepare the same standard in a simple buffer such as phosphate-buffered saline. Measure both standards with your chosen assay. If the readings differ by more than 10 percent, your buffer is interfering with the assay.

Next, prepare a dilution series of your actual sample and measure each dilution. Calculate the protein concentration for each dilution. If the calculated concentration is consistent across dilutions, your sample is free of significant interference. If the concentration changes with dilution, interference is present and you need to either change assays or remove the interfering substance.

A more rigorous validation involves spiking a known amount of protein standard into your sample and measuring the recovery. Add a small volume of concentrated protein standard to your sample, measure the protein concentration, and calculate the difference between the spiked and unspiked samples. The difference should equal the amount of protein you added. Recovery between 90 and 110 percent indicates acceptable assay performance.

Record the results of your validation in your laboratory notebook or electronic records. Include the assay type, buffer composition, standard used, dilution factors, and calculated concentrations. This record allows you to compare results across experiments and to identify problems if measurements become inconsistent later.

For quantitative applications such as determining yield from a purification step or normalizing samples for downstream analysis, validation is essential. For qualitative applications where you only need to know whether protein is present, a simple compatibility check may suffice. The level of validation should match the importance of the measurement.

Removing Interfering Substances from Protein Samples

When your buffer contains substances that interfere with your chosen assay, you must remove them before quantification. The removal method should be compatible with your protein and should not introduce new interferences. The table below compares common removal methods.

Dialysis uses a semipermeable membrane that allows small molecules to pass while retaining proteins. The sample is placed in a dialysis bag or cassette and immersed in a large volume of buffer. Small molecules diffuse out until equilibrium is reached. The process takes several hours and requires multiple buffer changes for complete removal. Dialysis is gentle and preserves protein activity, making it suitable for sensitive proteins.

Desalting columns contain size-exclusion resin that separates proteins from small molecules. The sample is applied to the column, and protein elutes in the void volume while small molecules are retained. The process takes minutes instead of hours, but the sample is diluted by approximately 1.5 to 2 fold. Protein recovery depends on the column and the protein, typically ranging from 70 to 95 percent.

Acid precipitation with trichloroacetic acid (TCA) or acetone denatures and precipitates protein while leaving many small molecules in solution. The precipitated protein is collected by centrifugation, washed to remove residual precipitant, and resolubilized in a buffer of your choice. This method concentrates dilute protein samples and removes detergents effectively. However, some proteins do not precipitate efficiently, and resolubilization can be incomplete, leading to protein loss.

Ultrafiltration uses a membrane with a molecular weight cutoff to retain protein while allowing small molecules to pass. The sample is placed in a centrifugal filter device and spun until the desired volume is reached. This method concentrates protein and removes small molecules simultaneously. Recovery is generally high, but some proteins bind to the membrane, and the process can take 15 to 60 minutes depending on the sample volume and membrane.

After removing interfering substances, verify that the removal was complete by measuring the protein concentration and checking for consistency with your validation results. If the concentration is lower than expected, protein may have been lost during the removal process. If the concentration is higher than expected, residual interfering substances may still be present.

Common Failure Patterns and Troubleshooting

Protein quantification problems often follow recognizable patterns. Recognizing these patterns helps you identify the cause and apply the correct fix without repeating failed experiments.

The first common pattern is inconsistent results across dilutions. If your calculated protein concentration decreases as you dilute the sample, you likely have an interfering substance that is being diluted below its threshold. If the calculated concentration increases with dilution, you may have a substance that enhances the assay signal at low concentration, or your standard curve may be nonlinear in the range you are measuring.

The second pattern is poor recovery in spike-and-recovery experiments. If you add a known amount of protein to your sample and recover less than 90 percent, something in your sample is suppressing the assay signal. This suppression could come from a reducing agent in a copper-based assay, a detergent in a dye-binding assay, or a substance that quenches fluorescence. If you recover more than 110 percent, something is enhancing the signal, such as a reducing agent in a BCA assay or a substance that absorbs at the measurement wavelength.

The third pattern is high background in blank samples. If your buffer alone produces a signal significantly above zero, the buffer contains a substance that reacts with the assay reagents. This pattern is common with BCA assays in the presence of reducing agents and with Bradford assays in the presence of detergents. Check your blank readings before measuring samples, and if the blank is high, identify and remove the interfering substance.

The fourth pattern is poor reproducibility between replicate measurements. If replicate wells or replicate dilutions give widely varying readings, the problem may be pipetting error, incomplete mixing, or precipitation in the reaction. Ensure that all reagents are mixed thoroughly and that no precipitate forms during incubation. If precipitation occurs, the assay conditions may need adjustment.

The fifth pattern is a standard curve that does not fit the expected relationship. Most colorimetric assays produce a linear response over a limited concentration range. If your standard curve is nonlinear, you may be measuring outside the linear range, or the standard may be degraded or incorrectly prepared. Prepare fresh standards and measure a wider dilution series to identify the linear range.

When you encounter any of these patterns, document the observations in your records. Include the assay type, buffer composition, sample preparation steps, and the specific readings you obtained. This documentation helps you identify the cause and provides a reference for future troubleshooting.

Quality Controls and Measurement Records

Reliable protein quantification requires consistent quality controls and careful record keeping. These practices allow you to detect problems early and to compare results across experiments performed at different times.

Include a standard curve on every plate or batch of samples. The standard curve should use the same protein standard and buffer as your samples. Record the absorbance or fluorescence values for each standard and fit a curve to the data. The curve should be linear over the range you are using, and the R-squared value should be at least 0.98 for quantitative work.

Include a blank that contains all reagents but no protein. The blank reading should be subtracted from all sample readings. Record the blank value and check that it remains consistent across experiments. A rising blank may indicate reagent degradation or contamination.

Include a quality control sample of known concentration in every batch. This sample should be a protein standard prepared in the same buffer as your samples. The measured concentration should fall within 10 percent of the expected value. If the quality control fails, the assay results for that batch are suspect.

Record the following information for every protein quantification experiment: assay type, reagent lot numbers, standard protein and concentration, buffer composition, sample preparation steps, incubation time and temperature, absorbance or fluorescence readings, calculated concentrations, and any observations about unusual color, precipitation, or turbidity. This record allows you to trace problems back to specific reagents or steps.

For experiments that will be published or used for regulatory submissions, follow the measurement quality principles recommended by the National Institute of Standards and Technology. These principles include using calibrated pipettes, verifying reagent performance, and documenting all measurement conditions. Consistent application of these principles improves the reliability and comparability of your results.

Biosafety and Sample Handling Considerations

Protein quantification often involves samples from biological sources, including cell lysates, tissue extracts, and clinical specimens. These samples may contain infectious agents, toxins, or other hazardous materials. Handle all biological samples according to the biosafety principles described in the Biosafety in Microbiological and Biomedical Laboratories guidelines from the CDC and NIH.

Assess the risk of each sample before beginning work. Consider the source of the sample, the potential for infectious agents, and the procedures you will perform. Samples from human or animal sources may contain bloodborne pathogens or other infectious agents. Samples from recombinant organisms may be subject to the NIH Guidelines for Research Involving Recombinant or Synthetic Nucleic Acid Molecules.

Perform work with biological samples in a biosafety cabinet when aerosol generation is possible. Pipetting, vortexing, and centrifugation can generate aerosols that may contain infectious agents. Use appropriate personal protective equipment, including gloves and a lab coat, and decontaminate work surfaces after completing the procedure.

Some protein assay reagents are hazardous. The Folin-Ciocalteu reagent used in the Lowry assay contains strong acid. Coomassie dye used in the Bradford assay may be an irritant. Handle all reagents according to the safety data sheets and use appropriate precautions.

Dispose of biological samples and assay reagents according to your institution's waste disposal policies. Do not pour biological samples down the drain without appropriate decontamination. Collect contaminated materials in appropriate waste containers and arrange for proper disposal.

Interpreting Results in the Context of Downstream Applications

The purpose of protein quantification determines the level of accuracy you need. For some applications, an approximate concentration is sufficient. For others, precise quantification is critical.

For normalizing samples before gel electrophoresis, a rough estimate of protein concentration is usually adequate. Load equal amounts of protein based on your quantification, and verify equal loading by staining the gel. If the bands appear uneven, adjust the loading volumes accordingly.

For determining yield from a purification step, accurate quantification is important. The yield calculation depends on the total protein measured in the starting material and the purified fraction. If your assay overestimates or underestimates protein, the yield calculation will be correspondingly wrong. Validate your assay for the specific buffers used in each purification step.

For preparing samples for mass spectrometry, accurate quantification is essential because the amount of protein loaded affects the quality of the data. Overloading can cause contamination and poor ionization, while underloading may result in insufficient signal. Use a validated assay and include appropriate controls.

For clinical applications such as measuring thyroglobulin in fine-needle aspiration washout, the accuracy of the protein measurement can affect diagnostic decisions. The systematic review of thyroglobulin measurement in lymph node fine-needle aspiration washout demonstrates that this measurement has high diagnostic accuracy for detecting cervical lymph node metastases in papillary thyroid carcinoma. The reliability of such measurements depends on validated assays and appropriate quality controls.

For research applications involving single-cell analysis, the sensitivity of the assay becomes critical. Studies of protein expression in individual oocytes have used liquid chromatography-tandem mass spectrometry to identify differentially expressed proteins, demonstrating that highly sensitive methods are needed when sample quantities are limited. Standard colorimetric assays lack the sensitivity for single-cell work and require more advanced instrumentation.

When interpreting protein quantification results, consider the limitations of your assay. No assay measures absolute protein concentration with perfect accuracy. The calculated concentration depends on the standard used, the protein composition of your sample, and the absence of interfering substances. Report the assay type and standard used when presenting protein concentrations so that others can interpret your results appropriately.

Professional Escalation Criteria

Some protein quantification problems require consultation with a more experienced colleague, a core facility director, or the manufacturer of the assay reagents. Recognize when your troubleshooting efforts are not resolving the problem and seek help.

Escalate to a supervisor or core facility director if you cannot achieve consistent results after repeating the validation workflow. Persistent inconsistency may indicate a problem with reagents, equipment, or technique that requires expert diagnosis.

Escalate to the assay manufacturer if the assay does not perform according to the product documentation. Manufacturers can provide technical support and may have information about compatibility with specific buffers or interfering substances. Provide them with your buffer composition, sample type, and the specific readings you obtained.

Escalate to a biosafety officer if you are working with samples that may contain infectious agents and you are uncertain about the appropriate containment level. The biosafety officer can help you assess the risk and implement appropriate controls.

Escalate to an institutional biosafety committee if your work involves recombinant or synthetic nucleic acid molecules and you are uncertain about the applicable NIH Guidelines. The committee can provide guidance on containment and oversight requirements.

Escalate to a statistician or methodologist if you are developing a new quantification method or adapting an existing method for a novel sample type. Statistical expertise can help you design validation experiments and interpret the results appropriately.

Building a Decision Framework for Assay Selection Under Realistic Laboratory Constraints

Choosing a protein assay is rarely a one-time decision. The same laboratory may process samples from cell lysates, purified fractions, column elutions, and tissue extracts within a single week, each with different buffer compositions and expected protein concentrations. A decision framework that accounts for your actual constraints, instead of a generic compatibility chart, reduces wasted reagents, repeated measurements, and unreliable data. This section provides a structured approach to assay selection that you can adapt to your specific workflow.

Step 1: Inventory Your Sample Matrix Before Choosing an Assay

The most common mistake in assay selection is choosing the assay first and checking buffer compatibility second. Reverse this order. Before you open any reagent bottle, write down the complete composition of your sample buffer. Include every component at its working concentration, beyond the major buffer salt. A sample that contains 25 mM Tris, 150 mM NaCl, 1 mM EDTA, and 0.1 percent SDS requires a different assay choice than the same sample without SDS.

Create a buffer inventory sheet for each sample type you process regularly. List the buffer name, pH, salt concentration, detergents, reducing agents, chelators, and any proprietary additives. Note the expected protein concentration range based on previous measurements or the source of the sample. This sheet becomes the first reference point in your assay selection process.

For samples from cell lysates, consider whether the lysis buffer contains protease inhibitors. Many protease inhibitor cocktails include EDTA or other chelators that interfere with copper-based assays. For samples from inclusion body preparations, note whether guanidine or urea is present at high concentration. For samples from membrane protein extractions, expect detergents at concentrations that may exceed the tolerance of dye-binding assays.

The Addgene protocol collection provides practical examples of common lysis buffer formulations used in molecular biology workflows. While individual protocols vary, reviewing these formulations helps you anticipate which interfering substances appear together in typical sample preparation schemes.

Step 2: Rank Assay Options by Interference Risk and Sensitivity

After documenting your sample matrix, rank the candidate assays using three criteria: interference risk with your specific buffer, sensitivity relative to your expected protein concentration, and protein-to-protein variability. This ranking forces you to consider trade-offs explicitly instead of defaulting to the assay you used last time.

Interference risk comes first. If your buffer contains a reducing agent at a concentration that interferes with copper-based assays, BCA, Lowry, and biuret drop off the list regardless of their other advantages. If your buffer contains ionic detergents, Bradford becomes problematic. If your buffer contains imidazole above approximately 100 mM, A280 is unreliable. Apply these filters before considering sensitivity.

Sensitivity comes second. Match the assay working range to your expected protein concentration. For purified proteins at concentrations above 0.5 milligrams per milliliter, A280 or biuret may be adequate. For dilute samples below 50 micrograms per milliliter, you need a more sensitive method such as Bradford, BCA, or a fluorometric assay. Using an insensitive assay on a dilute sample produces readings near the detection limit where measurement error dominates.

Protein-to-protein variability comes third. If your standard protein differs substantially from your sample protein in amino acid composition, Bradford and Lowry will produce biased results. BCA and A280 show less variability between proteins, though A280 depends heavily on tryptophan and tyrosine content. For samples where the protein identity is unknown or heterogeneous, such as total cell lysates, choose an assay with lower protein-to-protein variability.

Step 3: Apply the Dilution Feasibility Test

Before committing to a removal method, test whether simple dilution can bring interfering substances below their threshold concentrations. This test takes minutes and can save hours of dialysis or precipitation.

Prepare a dilution series of your sample in the assay diluent recommended by the manufacturer. Measure each dilution with your candidate assay. Calculate the apparent protein concentration for each dilution. If the calculated concentration remains within 10 percent across a four-fold dilution range, interference is likely negligible at those dilutions. If the calculated concentration changes systematically with dilution, interference is present.

The dilution feasibility test also reveals whether your protein concentration remains detectable after dilution. A sample at 2 milligrams per milliliter with 5 mM DTT may require a 10-fold dilution to bring DTT below the interference threshold for BCA, but that dilution brings protein to 200 micrograms per milliliter, which is still within the BCA working range. The same approach fails for a sample at 50 micrograms per milliliter with the same DTT concentration, because the required dilution pushes protein below the detection limit.

Document the results of this test in your records. The dilution factor that eliminates interference becomes part of your standard protocol for that sample type. If dilution is not feasible, proceed to removal methods.

Step 4: Match Removal Methods to the Interfering Substance

When dilution is not feasible, select a removal method based on the chemical properties of the interfering substance and the stability of your protein. The table below organizes removal strategies by interference class.

Reducing agents are small molecules that separate readily from protein using desalting columns. The rapid processing time minimizes protein oxidation during the removal step. For larger volumes or when desalting columns are unavailable, dialysis works but requires multiple buffer changes and several hours.

Chelators such as EDTA require more extensive removal because they bind divalent cations and may remain associated with protein. Dialysis with multiple buffer changes is often more effective than a single desalting pass. Verify complete removal by testing whether the assay produces the expected signal with a known protein standard in the treated buffer.

Ionic detergents bind tightly to protein and resist removal by dialysis or desalting. Precipitation with acetone or TCA disrupts detergent-protein interactions and leaves the detergent in the supernatant. After centrifugation, wash the protein pellet to remove residual detergent before resolubilization.

Nonionic detergents at moderate concentrations may be handled by dilution if the assay tolerance allows. Triton X-100 at 0.1 percent is compatible with BCA and Pierce 660 nm, so dilution may not be necessary. At higher concentrations, ultrafiltration with a membrane that retains protein while allowing detergent monomers to pass can reduce the detergent burden.

Step 5: Establish a Per-Sample-Type Validation Record

For each sample type you process regularly, create a validation record that documents the assay choice, the dilution factor, the removal method if used, and the spike-and-recovery results. This record becomes your reference for future experiments and your evidence that the quantification method is fit for purpose.

The validation record should include the following fields: sample type, source, buffer composition, expected protein range, assay name, standard protein, dilution factor, removal method, spike recovery percentage, and the date of validation. Update the record whenever you change the buffer composition or switch assay reagents.

Store these records in a laboratory notebook or electronic system where they are accessible to everyone who performs protein quantification. When a new researcher joins the laboratory, the validation records tell them which method to use for each sample type without repeating the validation work. When results become inconsistent, the records help identify what changed.

The measurement quality principles promoted by the National Institute of Standards and Technology support this documentation approach. Consistent record keeping, calibrated equipment, and verified reagent performance form the foundation of reliable measurement across all laboratory applications.

Step 6: Apply the Decision Framework to Common Scenarios

The following scenarios illustrate how the decision framework works in practice.

Scenario one: You are quantifying protein in a nickel affinity column elution containing 250 mM imidazole and 300 mM NaCl. The expected protein concentration is 1 to 5 milligrams per milliliter. A280 is ruled out because imidazole absorbs at 280 nm. BCA, Bradford, and Pierce 660 nm are all compatible with imidazole at this concentration. The dilution feasibility test shows that a 5-fold dilution brings imidazole to 50 mM, which is acceptable for A280 if you prefer that method. Otherwise, BCA or Pierce 660 nm work without dilution. The decision depends on whether you need to conserve sample and whether reducing agents are present in the elution buffer.

Scenario two: You are quantifying total protein in a mammalian cell lysate prepared in RIPA buffer containing 0.1 percent SDS, 0.5 percent sodium deoxycholate, 1 percent NP-40, and 1 mM EDTA. Bradford is ruled out because the ionic detergents interfere. BCA is problematic because EDTA chelates copper. Pierce 660 nm tolerates these detergents and EDTA at the concentrations listed. The dilution feasibility test shows that a 2-fold dilution reduces the detergent concentrations while keeping protein detectable. Pierce 660 nm with a 2-fold dilution is the practical choice.

Scenario three: You are quantifying a purified enzyme stored in 50 mM Tris, 150 mM NaCl, 1 mM DTT, and 10 percent glycerol at a concentration of 0.2 milligrams per milliliter. BCA and Lowry are ruled out because DTT reduces copper. Bradford tolerates DTT but the glycerol at 10 percent may affect the dye binding. Pierce 660 nm tolerates both DTT and glycerol at these concentrations. A280 is feasible if the protein contains aromatic residues and the buffer components do not absorb at 280 nm. The dilution feasibility test confirms whether A280 works without interference.

Step 7: Review and Revise the Framework Periodically

Your sample types and buffer compositions will change as your research evolves. Review your validation records every three to six months and update them when you introduce new buffers, new sample sources, or new assay reagents. A decision framework that goes stale becomes as unreliable as no framework at all.

When you change a buffer component, even at a concentration that seems minor, revalidate the assay for that sample type. A change from 1 mM to 5 mM DTT can push a copper-based assay from acceptable to unreliable. A change from 0.1 percent to 0.5 percent SDS can make Bradford unusable. The validation record tells you which parameters matter for each assay and sample combination.

The MIQE guidelines, while developed for quantitative PCR, emphasize a principle that applies equally to protein quantification: transparency about methods and controls enables others to evaluate and reproduce your results. Documenting your assay selection rationale and validation data serves the same purpose in protein work.

Common Failure Patterns in Assay Selection

The decision framework prevents several recurring problems. The first is assay drift, where a laboratory continues using the same assay for years without rechecking compatibility as buffers change. The validation record catches this by requiring revalidation when buffer composition changes.

The second is sensitivity mismatch, where an assay is chosen for its interference tolerance without checking whether it can detect the expected protein concentration. The ranking step addresses this by forcing sensitivity to be considered alongside interference risk.

The third is over-reliance on a single removal method. Dialysis works for small molecules but fails for detergents. Precipitation works for detergents but may lose hydrophobic proteins. The removal method table matches the method to the interference class.

The fourth is failure to verify removal. Even the best removal method can fail silently. The spike-and-recovery control after removal confirms that the treatment worked and that protein was not lost in the process.

Records and Measurements for the Decision Framework

Maintain the following records to support your decision framework. First, the buffer inventory sheet listing every sample type and its complete buffer composition. Second, the validation record for each sample type with spike-and-recovery results. Third, the dilution feasibility test results showing the dilution factor that eliminates interference. Fourth, the removal method log documenting which method was used, the processing time, and the recovery percentage.

These records serve multiple purposes. They support troubleshooting when results become inconsistent. They provide evidence for publications and regulatory submissions. They train new laboratory members in established methods. And they document that your quantification approach was chosen deliberately instead of by habit.

For laboratories that process clinical samples or samples destined for diagnostic use, the documentation requirements are more stringent. The systematic review of thyroglobulin measurement in lymph node fine-needle aspiration washout illustrates how assay validation and quality control directly affect diagnostic performance. The same principles apply to research samples, though the documentation burden may be lighter.

Professional Escalation Criteria for Assay Selection Problems

Escalate to a supervisor or core facility director when you cannot identify an assay that meets both interference and sensitivity requirements for a new sample type. The problem may require a different assay format, such as switching from colorimetric to fluorometric detection, or a more extensive sample preparation protocol.

Escalate to the assay manufacturer when the product documentation does not address your specific buffer composition. Manufacturers maintain compatibility databases that may include information not in the product insert. Provide them with your complete buffer formulation and expected protein concentration.

Escalate to a biosafety officer if your sample matrix includes biological hazards that affect how you handle the sample during removal or dilution steps. The Biosafety in Microbiological and Biomedical Laboratories guidelines from CDC and NIH provide the framework for assessing these risks.

Escalate to a statistician when you need to establish the measurement uncertainty of your quantification method for a specific sample type. The decision framework identifies the method, but quantifying the confidence intervals around your measurements requires statistical expertise.

Frequently Asked Questions

Why does my BCA assay give falsely high readings when my sample contains DTT?

DTT is a reducing agent that reduces cupric ions to cuprous ions in the BCA reaction. The assay detects cuprous ions through their reaction with bicinchoninic acid, so any reducing agent in the sample produces signal independent of protein. Remove DTT by dialysis, desalting, or precipitation before using the BCA assay, or switch to a method that tolerates reducing agents such as Bradford or Pierce 660 nm.

Can I use the Bradford assay with samples containing SDS?

SDS interferes with the Bradford assay by binding to the Coomassie dye and causing precipitation or spectral shifts. At concentrations above approximately 0.1 percent, SDS produces significant interference. If your sample contains SDS, use a different assay such as BCA or Pierce 660 nm, or remove the SDS by precipitation before quantification.

What is the best way to remove imidazole from my protein sample before measuring A280?

Imidazole absorbs light at 280 nm and will inflate A280 readings. Dialysis or desalting columns effectively remove imidazole from protein samples. After removal, verify that the imidazole concentration is negligible by measuring the absorbance of the flow-through or dialysate. Alternatively, use a colorimetric assay that does not respond to imidazole.

How do I know if my protein assay is being affected by an interfering substance?

Perform a spike-and-recovery experiment by adding a known amount of protein standard to your sample and measuring the recovery. Recovery between 90 and 110 percent indicates acceptable assay performance. Also measure your sample at multiple dilutions and check that the calculated concentration remains consistent. If recovery is poor or concentration changes with dilution, interference is present.

Which protein assay is most tolerant of common buffer components?

The Pierce 660 nm assay was designed for compatibility with reducing agents and detergents at concentrations commonly used in protein research. It tolerates DTT, beta-mercaptoethanol, and many detergents better than BCA or Bradford. However, no assay tolerates every buffer component, so validate your specific buffer before relying on the results.

Can I measure protein concentration by A280 if my sample contains nucleic acids?

Nucleic acids absorb at 280 nm and will inflate your protein measurement. You can apply a correction based on the A260/A280 ratio, but this correction assumes a specific nucleic acid composition and introduces error. If nucleic acids are present in significant amounts, use a colorimetric assay that does not respond to nucleic acids, such as BCA or Bradford.

Why does my standard curve become nonlinear at high protein concentrations?

Most colorimetric assays have a limited linear range. At high protein concentrations, the assay reagents become limiting or the absorbance exceeds the linear response of the detector. Prepare a wider dilution series to identify the linear range of your assay and measure samples within that range. Dilute concentrated samples so that they fall within the linear portion of the curve.

What should I do if my protein quantification results are inconsistent between experiments?

Check your reagents for degradation, verify that your pipettes are calibrated, and confirm that your standards are freshly prepared. Document all measurement conditions and compare them across experiments. If inconsistency persists, escalate to a supervisor or the assay manufacturer for technical support.

Related Molecular Biology Guides

• Cryo-EM Protein Structure Determination: A Comprehensive Guide
• Protein Expression and Purification: A Practical Guide
• Instrumentation of Gel Chromatography: A Comprehensive Guide
• Automated Protein Quantification: Methods and Applications
• Protein Crystallization: Principles, Methods, and Applications

References and Further Reading

• Molecular Biology and Laboratory Methods. National Library of Medicine.
• Biosafety in Microbiological and Biomedical Laboratories. CDC and NIH.
• NIH Guidelines for Recombinant or Synthetic Nucleic Acid Molecules. National Institutes of Health.
• Addgene Protocols. Addgene.
• MIQE Guidelines. Clinical Chemistry.
• NIST Laboratory Programs. National Institute of Standards and Technology.
• Rapid identification of primary atopic disorders (PAD) by a clinical landmark-guided, upfront use of genomic sequencing.. Allergologie select, 2024.
• Single-cell proteomics analysis of human oocytes during GV-to-MI transition.. Human reproduction (Oxford, England), 2025.
• Hexokinase Method.. 2026.
• Diagnostic Efficiency of Thyroglobulin in Lymph Node Fine-needle Aspiration Washout: A Systematic Review and Meta-analysis.. The Journal of clinical endocrinology and metabolism, 2025.
• Decoding allergy in vitro: Challenges and clinical use of humoral and cellular methods.. Allergologie select, 2026.

This article is educational and does not replace validated laboratory procedures, institutional biosafety review, manufacturer instructions, or professional interpretation.